Abstract:

 Objective To evaluate the therapeutic efficacy and toxicity of celecoxib plus docetaxel and S-1 in the treatment of advanced gastric cancer. Methods Fifty patients with advanced gastric cancer were randomly divided into two groups，which were treated with celecoxib （Celebrex） plus docetaxel and S-1 （n=25），or with docetaxel and S-1 （n=25） as the control arm. Results After treatment，the total effective rate and disease control rate were 60% and 96% in the treatment group，compared to 52% and 92% in the control group.The groups were similar in terms of total effective rate and disease control rate（P>0.05）.Toxicity after treatment was minor in the two groups，and incidences of toxic events were similar between the two groups（P>0.05）.Improvement in quality of life was significantly higher in the treatment group than in the control group （60% vs 32%，P<0.05）.Median PFS was　7.6 months in the treatment group，which was significantly higher than　6.3　months in the control group（P<0.05）.Median overall survival was 13.6 months in the treatment group and 12.2 months in the control group （P>0.05）. Conclusions Celecoxib plus docetaxel and S-1 for advanced gastric cancer is superior to chemotherapy alone，and it can prolong PFS and improve quality of life without increasing adverse reactions.

Key words: Gastric neoplasms, Celecoxib, Advanced gastric cancer, Chemotherapy, COX